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Abstract: Alzheimer’s disease is the most common form of dementia in industrialized countries. 
In the European Union, about 54% of dementia cases are believed to be due to Alzheimer’s 
disease. The condition is an age-related neurodegenerative disorder characterized by multiple 
cognitive deﬁ  ciencies, including loss of memory, judgment, and comprehension. These 
manifestations are accompanied by behavioral and mood disturbances. Although no cure has 
yet been discovered for Alzheimer’s disease, symptomatic therapies are now widely available 
and offer signiﬁ  cant relief to patients and beneﬁ  ts to caregivers in terms of reduced care burden. 
At the start of the 21st century, health technology assessments recommended three agents for 
the symptomatic treatment of mild to moderate Alzheimer disease: rivastigmine, donepezil, 
and galantamine. Rivastigmine (Exelon®, Novartis Basel—Switzerland) is a slowly reversible 
inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), while donepezil 
(Aricept®, Pﬁ  zer, New York, USA) and galantamine (Reminyl®, Janssen, New Jersey,USA) 
show no functional inhibition of BuChE, and are considered AChE-selective, rapidly-reversible 
inhibitors. The efﬁ  cacy of all three agents has been evaluated in large, double-blind, placebo-
controlled clinical trials of up to 6 months’ duration. Rivastigmine treatment in mild to moderate 
Alzheimer’s disease improves cognition, activities of daily living, and global function.
Keywords: acetylcholinesterase inhibitors, Alzheimer’s disease, donepezil, galantamine, 
rivastigmine.
Alzheimer’s disease: clinical features
The symptoms of Alzheimer’s disease (AD) are directly related to the degeneration of 
cholinergic neurons of the cortex and hippocampus, which results in lower levels of 
acetylcholine and a reduction of cholinergic transmission (Davies and Maloney 1976). 
This cholinergic hypothesis led to the development of cholinesterase inhibitors, which 
act by inhibiting the two enzymes responsible for the degradation of acetylcholine: 
acetylcholinesterase (AChE) or butyrylcholinesterase (BuChE). 
Cholinesterase (ChE) inhibitors are currently a symptomatic intervention for 
AD. Their clinical beneﬁ  t is thought to derive primarily from an increase in synaptic 
acetylcholine (ACh) levels, leading to enhanced cholinergic neurotransmission which 
improves activities of daily living (ADL), behavior, and cognitive performance.
At the start of the 21st century, health technology assessments recommended 
three agents for the symptomatic treatment of mild to moderate AD: rivastigmine, 
donepezil, and galantamine (Clegg et al 2001; Doody et al 2001). Rivastigmine 
(Exelon®, Novartis, Basel, Switzerland) is a slowly reversible inhibitor of AChE 
and BuChE, while donepezil (Aricept®, Pﬁ  zer, New York, USA) and galantamine 
(Reminyl®, Janssen, New Jersey, USA) show no functional inhibition of BuChE, 
and are considered AChE-selective, rapidly-reversible inhibitors (Weinstock 1999). Clinical Interventions in Aging 2007:2(1) 18
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The efﬁ  cacy of all three agents have been evaluated in large, 
double-blind, placebo-controlled clinical trials of up to 6 
months duration.
Rivastigmine tartrate is a pseudo-irreversible, carbamate 
inhibitor that inhibits both AChE and BuChE selective 
for the brain compared with that in peripheral tissue. As a 
carbamate, rivastigmine binds to AChE which cleaves the 
rivastigmine molecule, releasing a phenolic cleavage product 
that is almost pharmacologically inert and is rapidly excreted 
via the kidneys.
The carbamate moiety remains bound to the esteratic site 
of the enzyme for much longer than is the case for the acetate 
moiety during the hydrolysis of ACh so that the enzyme is 
inactivated for some time after the parent molecule has disap-
peared from the circulation. The other consequence of this 
mechanism of action is that rivastigmine does not rely upon 
the hepatic cytochrome P450 system for either inactivation 
or elimination.
As rivastigmine has relatively low protein-binding 
characteristics, the potential for signiﬁ  cant interactions with 
other drugs is minimal, which is an important feature for a 
medication intended for use in elderly individuals who typi-
cally take many different medications for concurrent illnesses 
(Table 1). Rivastigmine also exhibits selectivity for the G1 
form of AChE and BuChE. The enzyme exists in several 
forms, the most abundant and important of which in normal 
individuals is the G4 form. With aging, and especially in 
AD, however, the amount of the G4 form of AChE falls 
progressively and it has been postulated that the G1 form 
plays a progressively more important role in hydrolyzing 
ACh at cholinergic synapses as AD advances. Rivastigmine 
inhibits the G1 form, which may mean that its efﬁ  cacy will 
be presented.
It shows preferential selectivity for the hippocampus 
and cortex (Darvesh et al 1998), those regions of the brain 
in which cholinergic deﬁ  cits are most pronounced in AD. 
This results in higher synaptic levels of the neurotransmit-
ter and improved function of cholinergic receptors. It has 
been proposed that since both AChE and BuChE degrade 
acetylcholine in the human brain (Mesulam et al 2002), the 
inhibition of both enzymes may lead to more potent bio-
logical effects, and greater, more sustained clinical beneﬁ  ts 
(Greig et al 2001; Ballard 2002; Poirier 2002).
Acetylcholinesterase and BuChE are two enzymes that 
have different roles in healthy individuals and subjects with 
AD. In healthy individuals, 80% of the enzymatic activity 
is carried out by AChE located predominantly in neurons. 
AChE is highly selective for acetylcholine hydrolysis, where-
as BuChE also acts on substrates. It has been shown (Xie et al 
2001) that in the case of AChE deﬁ  ciency, BuChE is capable 
of compensating for AChE function. The two enzymes can 
be distinguished in terms of kinetics, in that AChE is more 
efﬁ  cient at low substrate concentrations and inhibited at high 
concentrations. At high concentrations BuChE becomes very 
efﬁ  cient, and it probably supports the hydrolysis of excess 
AChE. Both BuChE and AChE exist in different forms: a 
G4 comprised of 4 globular proteins and a G1 form with a 
single subunit. The G1 and G4 forms are present in different 
brain regions. The G4 form is more abundant in healthy sub-
jects, whereas the G1 form plays a minor role. In AD, AChE 
Table 1 Pharmacological features of rivastigmine
Variable
Class Carbamate
No. daily doses  2
ChE inhibition
 Reversibility  Pseudoreversibile
  BuChE/AchE ratio in vitroa 1.9
Elimination/metabolism Renal
ADAS-cog changeb –4.94;  –2.58





Other (≥10%)  Asthenia, headache, dizziness
Notes: aRatio of IC50s (concentrations of drug required to inhibit BuChE and AchE activity by 50%). A smaller ratio indicates greater relative inhibition of BuChE; bMean 
difference in ADAS-Cog scores at trial end-point (12 to 30 weeks) between active treatment and placebo in pivotal trials (2 pivotal trials for each drug except galantamine; 
range given for 4 trials for this drug); cPercentage of patients completing the pivotal trials (2 trials for each drug except galantamine; dAs assessment by the total NPI score. 
Abbreviations: AChE, acetylcholinesterase;   ADAS-cog, Alzheimer’s Disease Assessment Scale—cognitive suscale;  BuChE, butyrylcholinesterase; CPY, cytochrome P450 
enzyme; NPI, Neuropsychiatric Inventory score; +, indicates improvement. Clinical Interventions in Aging 2007:2(1) 19
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activity is reduced to 55%–65%, whereas BuChE activity is 
increased and the ratio of BuChE to AChE changes from 0.5 
to 11 and eventually activity becomes exclusively BuChE. 
It has been shown that BuChE may also have a role in the 
aggregation of β-amyloid (Aβ) that occurs in the early stages 
of AD and above all in the stages of senile plaque formation 
(Perry et al 1978; Guillozet et al 1997). Both AChE and 
BuChE accumulate within the plaques and in the neuroﬁ  brillary 
tangles (Mesulam and Geula 1994). In AD, the G1 form of 
BuChE increases by 30%–60% and accumulates in the beta-
amyloid plaques, which are correlated to plaque density and 
pathogenicity. The K variant of BuChE may be associated 
with a greater susceptibility for developing AD, in particular 
in subjects who carry the apolipoprotein E4 (ApoE4) allele. 
Rivastigmine, which inhibits both AChE and BuChE, has 
been shown to protect against the formation of Aβ.
Pharmacokinetics
The absorption time of rivastigmine after oral administration 
(tmax) ranges from 0.8 to 167 hours. Absorption is >90%. 
Concomitant food intake reduces absorption of the drug and 
decreases concentration by 30%. Protein binding is quite low 
at approximately 40%; 40%–50% of the drug is associated 
with red blood cells. Rivastigmine is converted immediately 
to ZNS 144-666 at the site of action in the central nervous 
system (CNS) by cholinesterases and then enters the hepatic 
blood stream where it undergoes N-demethylation. The 
agent’s elimination half-life is less than two hours. Elimina-
tion is complete (90%) 24 hours after administration. The 
cerebrospinal ﬂ  uid (CSF) concentration of rivastigmine falls 
rapidly with a tmax of 1.4–3.8 hours and the drug is eliminated 
rapidly from the CSF with a half-life of 0.31–0.95 hours. A 
dose-dependent relationship was identiﬁ  ed at the CSF level, 
with inhibition of both AChE and BChE. For dosages of 2, 
6, 10, and 12 mg/day mean AChE inhibition was 20%, 46%, 
55.6%, and 61.7%, whereas BChE inhibition was 23.9%, 
76.6%, 54.9%, and 61%, although wide variability among 
patients was observed for the BChE values.
Drug interactions
Rivastigmine is not signiﬁ  cantly metabolized by the hepatic 
microsomal cytochrome P450 system because of its low 
protein binding, so no clinically signiﬁ  cant drug interactions 
are expected. Studies on healthy volunteers support this 
hypothesis (Anand et al 1996; Spencer and Noble 1998). In 
fact no interactions have been reported between rivastigmine 
and dygoxin, warfarin, diazepan, or ﬂ  uoxetine (Polinsky 
1998; Grossberg et al 2000). In addition, Polinsky’s retro-
spective analysis of clinical trials demonstrated no increase 
in adverse events relative to placebo in patients who were 
taking antianginal agents, antiacids, antihypertensive agents, 
calcium channel blockers, estrogens, antihistamines, and 
benzodiazepines.
Efﬁ  cacy of rivastigmine in 
subjects with mild and moderate 
Alzheimer’s disease
Rivastigmine, like other cholinesterase inhibitors, produces 
modest improvements in cognitive function and slows cog-
nitive decline versus placebo. Rivastigmine has been evalu-
ated in the treatment of subjects with mild to moderate AD. 
The primary indicators of response to treatment in AD are: 
the Alzheimer’s Disease Assessment Scale–Cognitive sec-
tion (ADAS-Cog), which assesses cognitive function, and 
the Clinician Interview-Based Impression of Change-plus 
(CIBIC-plus), which evaluates global function. 
The ADAS-cog has a score ranging from 0 to 70, with 
higher scores indicating greater alterations of cognitive 
function (memory, language, orientation, and executive 
function). Only the patient is assessed. Data from clinical 
trials are presented as changes or delta, indicating changes 
in score relative to baseline.
The 7-point CIBIC assesses global change relative to base-
line and measures cognitive, behavioral, and functional symp-
toms based on interviews with the patient and the caregiver (1, 
marked improvement; 4, no change; 7, marked decline). 
Secondary measures of clinical efﬁ  cacy of the drug are the 
Mini Mental State Examination (MMSE) and the caregiver-
rated Progressive Deterioration Scale (PDS). The MMSE has 
a maximum score of 30, and high scores above 26 indicate 
mild cognitive deterioration. The PDS is a second-choice 
test that measures the ADL and includes an assessment of 
the caregiver’s quality of life. The PDS is made up of 29 
items with a total score between 0 and 100. Clinical trials 
typically report changes relative to baseline. Instruments 
used to evaluate the efﬁ  cacy of rivastigmine in treating AD 
are shown in Table 2.
Two multicenter trials of rivastigmine have been con-
ducted on patients aged 45 to 90 years randomized to placebo 
or rivastigmine at a dose of 1–4 mg/day or 6–12 mg/day in 
a forced-dosage titration scheme. The assessment tools used 
were: ADAS-cog, CIBIC, PDS, and MMSE conducted at 
baseline and after 12, 18, and 26 weeks of treatment (Table 3). 
In the two combined studies, the completion rates for placebo, 
rivastigmine 1–4 mg/day, and rivastigmine 6–12 mg/day Clinical Interventions in Aging 2007:2(1) 20
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were 85%, 85%, and 66%, respectively. The main cause of 
drop-outs were adverse events. In one trial (Corey-Bloom 
et al 1998), efﬁ  cacy measured with ADAS-cog, CIBIC, and 
MMSE was dose-dependent in patients receiving 6–12 mg. 
This group of subjects demonstrated a greater improvement 
compared with the placebo group from baseline to 26 weeks. 
The study by Rosler and colleagues (1999) found that cogni-
tive function worsened progressively in the placebo group, 
with a mean deterioration of 1.41 points over the 29 weeks 
of treatment. ADAS-cog improved by 1.17 in subjects treated 
with high-dose rivastigmine. The difference between the two 
groups (placebo vs rivastigmine 6–12 mg) was statistically 
signiﬁ  cant at week 12, 18, and 26 of treatment. As regards 
the CIBIC at week 26, subjects treated with placebo dem-
onstrated a mean decline of 4.34 points. Instead, the patients 
treated with high doses of rivastigmine demonstrated a mean 
improvement of 3.93 points. PDS scores at week 26 showed 
a statistically signiﬁ  cant difference between patients on pla-
cebo and those receiving high-dose rivastigmine. At 26 weeks 
the subjects who received high-dose rivastigmine showed a 
signiﬁ  cant improvement on MMSE and PDS compared with 
the placebo group.
The PDS was used to assess ADL (eg, ability to dress 
and eat independently, social interaction, participation in 
housework and hobbies, awareness of time, and handling 
of ﬁ  nancial matters) in trials with rivastigmine. After 26 
weeks of treatment, signiﬁ  cantly more patients receiving 
rivastigmine 6–12 mg/day showed a ≥10% improvement in 
the PDS score compared with placebo in both trials (25 and 
29% vs 15% and 19%; p < 0.01) (Corey-Bloom et al 1998; 
Rosler et al 1999).
Two pivotal trials have shown that rivastigmine 6–12 
mg/day signiﬁ  cantly improved cognitive function (assessed 
by the ADAS-cog) after 26 weeks of treatment compared 
with placebo in patients with mild to moderate probable AD 
(Corey-Bloom et al 1998; Rosler et al 1999). The effects of 
Table 2 Instruments used to evalutate the efﬁ  cacy of rivastigmine in treating Alzheimer’s disease
  Symptoms or domains  Source of  Range of scale and
Instrument assessed  information  interpretation
Valutation of cognitive functions
Alzheimer’s disease   Cognition (memory, language,  Patient  0–70 points 0 = no errors
assessment scale   orientation, praxis)    70 = severe impairment
Mini Mental State   Cognition (memory, language,     0–30 points;30 = no errors,
Examination  orientation, attention, praxis),  Patients   0 = severe impairment
Valutation of global functions
Clinician interview   Global assessment of behaviour,  
based impression of   general psychopathology,   Patient and caregiver  1–7 points 1,2,3 = minimal improvement 4 = no
change scale   cognition,and activities of daily living    change 5,6,7 = marked deterioration   
Progressive   Activities of daily living   Caregiver  29 items Scores range from 0 to 100
deterioration scale
Table 3 Summary of rivastigmine clinical trials
Study   No.   Study duration  Dosage  Results (%) at week 26 vs       
 of  Pts  (wks)  (mg/day)  Baseline
      ADAS-cog  CIBIC-plus  MMSE
Agid et al 1998  402  13  Placebo  Not done  29.9a 0.0   
     4  Not  done  31.5  0.0
     6  Not  done  42.7  0.3
Corey-Bloom et al 
1998 699  26  Placebo  4.15  4.39  –0.79
     1–4  2.27  4.23b –0.33
     6–12  –0.79c 4.20d 0.30b
Rosler et al 1999  725  26  Placebo  1.34  4.38  –0.47
     1–4  1.37  4.24  –0.62
     6–12  –0.26b 3.91d 0.21b
Notes: asubjects scored 1 or 2; bp < 0.05; cp < 0.001; dp < 0.01. 
Abbreviations:  ADAS-cog, Alzheimer’s Disease Assessment Scale–Cognitive section; CIBIC-plus, Clinician Interview-Based Impression of Change-plus; MMSE, Mini Mental 
State Examination; Pts, patients. Clinical Interventions in Aging 2007:2(1) 21
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rivastigmine on cognitive function were dose related, with 
an estimated 0.28-point improvement in mean ADAS-cog 
score for every 1 mg/day increase in dosage (Anand et al 
2000). Rivastigmine was also superior to placebo (p < 0.01) 
on the CIBIC-plus scale, which measures global function-
ing (cognition, functioning, and behavior) (Farlow et al 
2000). Preliminary results from a long term extension study 
(Farlow et al 2000) of one of these trials (Corey-Bloom 
et al 1998) suggested that the beneﬁ  ts of rivastigmine, as 
measured by ADAS-cog scores, persisted over a 104-week 
study period. 
Rivastigmine had a positive effect on the rate of cognitive 
decline in subjects with severe AD. After 26 weeks, there 
was a small improvement (0.2) relative to baseline in the 
mean ADAS-cog score of subjects treated with rivastigmine, 
whereas there was a mean decline of 6.3 points in subjects 
receiving placebo (observed case [OC] population; p < 0.001). 
In the intention to treat-last observation carried forward (ITT-
LOCF) population there was no change from baseline in riv-
astigmine-treated subjects, compared with a 6.1-point decline 
in the placebo group (treatment difference, p < 0.001).
The efﬁ  cacy of rivastigmine was also assessed in terms 
of the proportion of subjects in whom cognitive function 
was sustained or improved from baseline after 6 months of 
treatment (mean change from baseline in ADAS-cog>0). In 
total, 46% of the subjects treated with rivastigmine either 
improved or showed no deterioration, compared with 9% of 
subjects treated with placebo (OC population; p < 0.001). The 
respective ﬁ  gures in the ITT-LOCF population were 44% for 
rivastigmine and 7% for placebo (p = 0.001).
After 26 weeks, subjects treated with rivastigmine showed 
a mean change from baseline of –0.8 points on the MMSE, 
compared with –2.5 points in the placebo group (OC popu-
lation; p = 0.02). The respective ﬁ  gures in the ITT-LOCF 
population were –0.8 and –2.5 points (p = 0.02).
Subjects on rivastigmine showed less decline of ADL 
than those on placebo. In the placebo group, functioning 
declined by a mean of 6.5 points in the PDS six-item score 
after 6 months. In contrast, the mean decline among subjects 
treated with rivastigmine was 1.6 points. In the ITT-LOCF 
population the decline was 2.0 points for rivastigmine and 
6.3 points for placebo.
The recommended dosage range for rivastigmine in pa-
tients with mild to moderate AD is 6–12 mg/day administered 
orally in two separate doses. Rivastigmine should be started 
at a dosage of 1.5 mg twice daily, and increased in 1.5-mg 
increments as tolerated. At least two weeks should separate 
each increase in dose 
To reduce the possibility of severe vomiting in patients 
who have interrupted rivastigmine therapy for more than 
several days, treatment should be restarted with the lowest 
daily dose. The dosage should then be titrated to the patient’s 
previous maintenance dosage 
Efﬁ  cacy of rivastigmine in 
subjects with moderate to severe 
Alzheimer’s disease 
The efﬁ  cacy of rivastigmine in the treatment of behavioral 
and psychological symptoms of dementia (BPSD) has also 
been studied in patients with moderate to severe AD living 
in long-term care facilities. 
A number of open-label prospective studies in nursing 
home patients have also investigated the effects of rivastig-
mine on neuropsychiatric and behavioral symptoms associ-
ated with AD (Cummings et al 2000a; Bullock et al 2001; 
Etemad et al 2001). One US study assessed the effects of 
26-weeks treatment with rivastigmine (3–12 mg/day) in 
173 patients with AD (mean MMSE = 9.2) (Cummings 
et al 2000a). Rivastigmine was associated with a signiﬁ  cant 
3.25-point overall decrease in the mean Neuropsychiatric In-
ventory–Nursing Home (NPI-NH) total score after 26 weeks, 
indicating that behavioral symptoms had improved. 
Similar data have been described in a interim report 
from a second US open-label 26-week study of rivastigmine 
(12 mg/day). Preliminary data obtained from 181 patients 
(MMSE = 10.6) reported that mean the NPI-NH total score 
decreased by approximately 4 points (Etemad et al 2001). 
In a 6-month study (Bullock et al 2001) in 113 patients with 
severe AD (mean MMSE = 10.9), >53% of patients showed 
improvements on all NPI-NH items and had a mean improve-
ment of 0.7 points on the MMSE. More than 40% of patients 
had ≥30% improvement from baseline in NPI-NH scores. 
Cummings (2003) conducted a prospective, 26-week, 
open-label study at 12 primary centers in a a total of 29 nurs-
ing homes in the US. The subjects were all nursing home 
residents with moderate to severe probable AD receiving 
rivastigmine 3–12 mg/day for 26 weeks. Following 6-months 
of rivastigmine treatment, a statistically signiﬁ  cant improve-
ment (p < 0.05) from baseline was observed in the following 
eight disturbances in subjects with that speciﬁ  c symptom 
present at baseline: delusion, hallucination, agitation, apathy/
indifference, irritability, aberrant motor behavior, night-time 
behavior, and appetite/eating change. There were statistically 
signiﬁ  cant improvements in depression/dysphoria, anxiety, 
euphoria/elation, and disinhibition. Clinical Interventions in Aging 2007:2(1) 22
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A prospective, multicenter 26-week open-label extension 
to a 26-week open-label study of rivastigmine treatment was 
carried out in patients with MMSE scores of 6–15 inclusive, 
residing in nursing home (Aupperle et al 2004). Rivastigmine 
(3–12 mg/day) signiﬁ  cantly improved neuropsychiatric and 
behavioral symptoms compared with baseline in observed 
cases and last observation carried forward analyses. Global 
function was stabilized or improved in more than half of 
the patients. 
A recent study (Doraiswamy et al 2001) demonstrated 
that cognitive function, ADL performance, and global 
function were signiﬁ  cantly better in patients treated with 
rivastigmine than those treated with placebo. The efﬁ  cacy 
of rivastigmine versus placebo in patients with moderate to 
moderately severe AD is shown in Figures 1, 2, and 3.
Effects on behavioral symptoms
Behavioral disturbances are a frequent occurrence in patients 
with AD and related dementia. Many of these behaviors 
are disruptive and unmanageable in the home care setting, 
resulting in the institutionalization of many patients. The 
peak intensity of different behavioral symptoms varies with 
disease severity and many of the symptoms are present long 
before the clinical diagnosis of the disease is established. 
Although antipsychotics have been somewhat effective in 
controlling the neuropsychiatric symptoms of AD, their use 
has been limited by side effects including extrapyramidal 
symptoms, sedation, dystonia, and hypotension. In addition, 
the use of psychotropic medication in this population to 
control behavioral abnormalities is tempered by the poten-
tial for overuse, resulting in chemical restraint. Therefore, 
a reduction in behavioral disturbances with a medication 
that lacks the traditional side effects of psychotropic drugs 
while improving other areas, such as cognitive and ADL, is 
an important treatment goal. 
There is growing evidence that, in addition to their effects 
on cognition, cholinesterase inhibitors also exert beneﬁ  cial 
psychotropic effects in patients with AD (Cummings et al 
2000a). Although this may be a class effect, it is possible 
that the exact effects and potency of each agent differ (Cum-
mings et al 2000a). 
Recent clinical data demonstrate that rivastigmine pro-
vides long-term improvement of behavioral symptoms in 
patients with AD, as assessed by either the patient or care-
giver. In patients with mild to moderate disease, rivastigmine 
improved or stabilized behavioral symptoms over a 2-year 
period. Although, as expected, the incidence of behavioral 
symptoms in this patient group was low, mood disorders 
Figure 1 Percentage of patients with moderate to moderately severe AD showing clinically relevant improvements on the ADAS-cog after 52 weeks. 
Notes: *p < 0.05 versus original placebo group; **p = 0.116 versus original placebo group.
Abbreviations: AD,   Alzheimer’s disease;   ADAS-cog,   Alzheimer’s Disease Assessment Scale–Cognitive section.
Placebo Rivastigmine ** 
6–12 mg
Placebo Rivastigmine * 
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(anxieties, phobias, and affective disturbances) were signiﬁ  -
cantly improved versus baseline (p = 0.001) and symptoms 
of aggression, activity disturbances, hallucinations, and 
paranoid and delusional symptoms were stabilized versus 
baseline after 2 years (Rosler et al 1998). 
In nursing-home patients with moderate to severe disease, 
rivastigmine improved behavioral symptoms as assessed by the 
NPI-NH scale for up to 1 year (Cummings et al 2000a, 2000b). 
Forty-nine percent of patients showed a ≥30% reduction from 
their baseline score after 52 weeks’ treatment (Cummings 
et al 2000a). This change is viewed as clinically signiﬁ  cant and 
similar to that achieved with conventional psychotropic agents. 
Almost half of the patient group who required antipsychotics 
at baseline no longer needed them after 52 weeks’ treatment 
with rivastigmine (Cummings 2000).
Further supportive evidence for the effects of rivastigmine 
on behavioral symptoms comes from a recent randomized, 
double-blind, placebo-controlled trial in patients with 
dementias with Lewy bodies (DLB). In this patient group, 
ﬂ  uctuating cognitive symptoms are also accompanied by 
neuropsychiatric symptoms including delusions, visual 
hallucinations, and sleep disturbances. Almost twice as many 
patients receiving rivastigmine (mean dosage 9.4 mg/day; 
n = 59) showed clinically relevant improvements on the 
NPI-NH as those treated with placebo after 20 weeks 
(n = 61) (McKeith et al 2000).
Figure 2. Percentages of patients in the high- and low-dose rivastigmine group and the placebo group on the PDS after 26 weeks. 
Note: * p = 0.02 vs placebo
Abbreviations: PDS, Progressive Deterioration Scale.
– –
Placebo Rivastigmine













Figure 3 Percentages of patients in the high- and low-dose rivastigmine group and the placebo group on CIBIC-plus after 26 weeks. 
Abbreviations: CIBIC-p, Clinician Interview-Based Impression of Change-plus.
Placebo Rivastigmine
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Meta-analyses evaluating the effects of rivastigmine on 
behaviors associated with mild to moderate AD have been 
performed and presented in poster form. Data were derived 
from a pooled population of 1840 patients for whom scores 
were available on the behavioral component of the Clinician’s 
Interview-Based Impression of Change Plus Caregiver Input 
Scale (CIBIC-plus adapted from BEHAVE-AD) from three 
6-month, double-blind, placebo controlled regulatory trials of 
rivastigmine in patients with mild to moderate AD (mean MMSE 
= 19.9) (Agid et al 1998; Corey-Bloom et al 1998; Rosler et al 
1999). The results after 6 months of treatment with rivastigmine 
6 to 12 mg/day suggested interesting differential effects on 
individual symptoms. Despite a strong placebo effect, patients 
with symptoms at baseline had signiﬁ  cant improvements in 
paranoid and delusional symptoms compared with placebo (p = 
0.002 and p = 0.046 respectively). With regard to the prevention 
of symptom emergence, rivastigmine treatment appeared to 
prevent the emergence of activity disturbances compared with 
placebo (p = 0.016). The authors of these poster presentations 
suggested that rivastigmine may improve existing psychotic 
symptoms in patients with mild to moderate AD. 
An open-label extension of a 6-month, double-blind, 
placebo-controlled regulatory study of rivastigmine in pa-
tients with mild to moderate AD (n = 725; mean baseline 
MMSE score, 10–26) reported signiﬁ  cant sustained effects 
on BPSD for up to 2 years (Rosler et al 1998). At all times 
after baseline, BPSD were signiﬁ  cantly better in the patients 
who had received rivastigmine for the entire study compared 
with those who had received placebo for the ﬁ  rst 6 months 
(p < 0.05). With regard to speciﬁ  c items on BEHAVE-AD, 
symptoms of hallucinations, aggressiveness, activity distur-
bances, and paranoid and delusional ideation were improved 
for ≥2 years in patients receiving rivastigmine. 
Rivastigmine has also demonstrated behavioral 
benefits in patients with DLB, including patients with 
both DLB and AD. In a double-blind, placebo-controlled 
study (n = 120; mean MMSE = 17.9) (McKeith et al 2000) 
in patients with DLB, receipt of rivastigmine 2 to 12 mg/day 
was associated with improvements in psychiatric symptoms 
as assessed using the NPI. Hallucinations and psychotic 
features resolved almost completely in more than half of 
patients receiving rivastigmine. At the end of the study 
period, NPI scores remained at baseline levels in patients 
who received rivastigmine for 96 weeks. 
An open-label exploratory study of rivastigmine (Reading 
et al 2001), in which patients were titrated over 6–8 weeks to 
the maximum tolerated dose and then maintained for a further 
6 weeks at this maximum dose, investigated the safety and 
tolerability in treating parkinsonian hallucinosis and cognitive 
impairment in diagnosed Parkinson’s disease patients with 
dementia and hallucinations. Signiﬁ  cant improvements from 
baseline in MMSE (20.4 to 25.4; p < 0.005) and total NPI (39.6 
to 15.2; p < 0.004) were seen in patients treated with rivastig-
mine. Hallucinations and sleep disturbances seemed particu-
larly sensitive to the effects of rivastigmine with signiﬁ  cant 
improvements in NPI (p < 0.03 and p < 0.02, respectively).
Tolerability
As with other cholinesterase inhibitors, the adverse events 
most commonly associated with rivastigmine are cholinergic 
in nature. These include nausea, vomiting, diarrhea, and an-
orexia and were reported in 14% to 50% of patients receiving 
rivastigmine 6 to 12 mg/day compared with 2% to 11% of 
placebo recipients in clinical trials (Corey-Bloom et al 1998; 
Rosler et al 1999). Other events occurring signiﬁ  cantly more 
frequently with rivastigmine 6 to 12 mg/day than with placebo 
are dizziness, headache, fatigue, malaise, sweating, asthenia, 
somnolence, dyspepsia, and sinusitis (p < 0.05).
Most events are mild to moderate in intensity, dose-
related, and of limited duration. In the pivotal clinical trials, 
adverse events were reported most frequently during the 
titration phase and may have been partly a function of the 
ﬁ  xed titration schedule demanded by the trial protocol. About 
one quarter of patients receiving rivastigmine 6 to 12 mg/day 
discontinued treatment because of adverse events (Corey-
Bloom et al 1998; Rosler et al 1999).
An episode of severe vomiting with esophageal rupture 
has been reported after re-initiation of rivastigmine therapy 
at an inappropriate single dose (4.5 mg) after treatment was 
interrupted for weeks (Babic et al 2000). No clinically rel-
evant changes in laboratory or vital signs (including hepatic 
enzymes) were observed with rivastigmine 6 to 12 mg/day, 
except for a ≥7% decrease in body weight reported in about 
one-ﬁ  fth of patients (Corey-Bloom et al 1998; Rosler et al 
1999). Common adverse events observed with rivastigmine 
therapy are shown in Figure 4 (Spencer and Noble 1998).
Comparative studies
All acetylcholinesterase inhibitors have proved to be more 
effective than placebo in randomized double-blind clinical 
trials. Lopez-Pousa and colleagues (2005) conducted a study to 
determine the differential efﬁ  cacy of the acetylcholinesterase 
inhibitors with respect to a historical sample of AD patients 
that were not treated. After a study period of 6 months they 
found no statistically signiﬁ  cant differences between done-
pezil, rivastigmine, and galantamine in terms of efﬁ  cacy, and Clinical Interventions in Aging 2007:2(1) 25
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all of the drugs signiﬁ  cantly slowed the decline in cognitive 
function associated with AD. Another study conducted by our 
group (Aguglia et al 2004) produced similar results. A sys-
tematic review (Takeda et al 2006) on the use of inhibitors has 
highlighted that the three drugs have similar efﬁ  cacy. Adverse 
effects are prevalently gastrointestinal in type and more com-
mon in treated patients (Clegg et al 2002; Wolfson et al 2002). 
The 2006 Cochrane Review states that there is no evidence 
of any difference with respect to clinical efﬁ  cacy despite the 
differences in the modes of action of the three inhibitors. From 
the point of view of adverse events, donepezil is the best toler-
ated, although gradual dose increments may prevent adverse 
events with rivastigmine and galantamine. 
A comparative study of the efﬁ  cacy and tolerability of 
donepezil and rivastigmine was conducted by Wilkinson and 
colleagues (2002) on 111 patients with mild to moderate AD. 
The two drugs (donepezil at 10 mg/day and rivastigmnine at 
12 mg/day) showed equal improvement in cognitive function 
on ADAS-cog at 4 and at 12 weeks from baseline, while 
donepezil was better tolerated than rivastigmine: 87.5% of 
donepezil-treated patients and 47.3% of rivastigmine-treated 
patients remained on the maximum approved dose of each 
drug until the end of the study.
Efﬁ  cacy of rivastigmine in dementia 
with Lewy bodies
The study by McKeith and colleagues (2000) is a multi-
center, placebo-controlled, double-blind study involving 
120 patients with DLB from Spain, the UK, and Italy. The 
subjects received 12 mg of rivastigmine daily or placebo 
for 20 weeks, followed by three weeks rest. Subjects were 
administered the NPI at baseline and at weeks 12, 20, and 
23; in addition, a computerized cognitive assessment system 
was used and the patients underwent physical examination 
and laboratory tests. The authors found that patients receiving 
rivastigmine were less apathetic and anxious and had fewer 
delusions and hallucinations than the control subjects. Com-
pared with the placebo group, patients receiving rivastigmine 
(37.63%) showed a 30% improvement from baseline in the 
computerized cognitive assessment and in the neuropsychi-
atric tests, as well as performing faster and better above all 
in the attentional tests. After discontinuation of treatment, 
the differences between rivastigmine and placebo tended to 
disappear. Adverse events (nausea, vomiting, and anorexia) 
were more frequent with rivastigmine than with placebo, but 
the safety and tolerability of the drug in these patients were 
judged acceptable. 
Rivastigmine treatment in AD improves cognition, ADL, 
and global function; rivastigmine is used in mild to moderate 
AD (Polinsky 1998; Wilkinson et al 2004). Rivastigmine 
binds to the AChE molecule in a pseudo-irreversible fashion; 
the acetyl moiety of AChE is dissociated rapidly, but the 
carbamyl moiety remains for some time longer. Rivastig-
mine is metabolized by the synapse rather than by hepatic 
cytochrome enzymes (Polinsky 1998). It has a half-life at 
the synapse of 9 hours and should be administered twice 
daily. The starting dose is 1.5 mg twice daily (3 mg/day), to 
be gradually increased to 6, 9, and 12 mg/day. A period of 
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1–2 weeks or more should separate each attempt to increase 
the dose, depending on patient tolerance.
Rivastigmine preferentially inhibits cerebrospinal ﬂ  uid 
(CSF) AChE over peripheral AChE or BuChE (Kennedy 
et al 1999). After treatment with rivastigmine for 12 months, 
activity of the CSF and plasma AChE decreases by 46% and 
that of BuChE by 65% relative to baseline (Darreh-Shori 
et al 2002). Rivastigmine causes a mild selective upregulation 
of AChE-R. Changes in the ratio of AChE-R-AChE-S splice 
variants correlated with sustained cognition at 12 months 
(Almkvist et al 2004; Darreh-Shori et al 2004). There is 
signiﬁ  cant correlation between plasma AChE inhibition and 
cognition, particularly as regards attention (Darreh-Shori et al 
2004). Rivastigmine seems to have some role in the modulation 
of amyloid precursor protein processing (Racchi et al 2004).
Rivastigmine at a dose of 6–12 mg/day appears to im-
prove or prevent disruptive behaviors and neuropsychiatric 
symptoms in patients with advanced AD (Finkel 2004). A 
recent study (Emre et al 2004) and a Cochrane review (Wild 
et al 2003) concluded that patients with DLB suffering from 
behavioral disturbances or psychiatric disorders beneﬁ  t from 
rivastigmine treatment, if they can tolerate it.
Rivastigmine for dementia 
associated with Parkinson’s disease
Emre and colleagues (2004) reported in selected patients 
who had received a clinical diagnosis of mild to moderate 
Parkinson’s disease over the past two years were random-
ized to placebo or rivastigmine 3–12 mg/day for 24 weeks. 
Efﬁ  cacy variables were the scores on the ADAS-Cog, ADCS-
CGIC (Alzheimer’s Disease Cooperative Study—Clinician’s 
Global Impression of Change), the MMSE, the 10-item NPI, 
Cognitive Drug Research power of attention tests, the Verbal 
Fluency test, and the CDT. 
A total of 541 patients were enrolled and 410 completed 
the study. The outcomes were better among patients treated 
with rivastigmine than among those receiving placebo; the 
differences between the two groups were, however, moderate 
and similar to those reported in trials of rivastigmine for AD. 
Patients treated with rivastigmine had a mean improvement of 
2.1 points in the 70-point ADAS-Cog score, from a baseline 
score of 23.8, as compared with a 0.7-point worsening in the 
placebo group, from a baseline score of 24.3 (p < 0.001). A 
clinically signiﬁ  cant improvement in the ADCS-CGIC scores 
was seen in 19.8% of patients in the rivastigmine group and in 
14.5% of those in the placebo group, and a clinically signiﬁ  -
cant worsening was seen in 13% and in 23.1%, respectively 
(mean score at 24 weeks, 3.8 and 4.3, respectively; p = 0.007). 
The most frequent adverse events were nausea (29.0% of 
patients in the rivastigmine-treated group and 11.2% of those 
in the placebo group), vomiting (16.6% and 1.7%, p < 0.001) 
and tremor (10.2% and 3.9%, p = 0.01). 
In this placebo-controlled study, rivastigmine was associ-
ated with a moderate improvement in dementia associated 
with Parkinson’s disease but also with higher rates of nausea, 
vomiting, and tremors.
Rivastigmine for vascular dementia
Kumar and colleagues (2000) reported that rivastigmine was 
associated with improvements in a wide range of efﬁ  cacy 
measures (cognitive performance, ADL, and disease sever-
ity) in patients with and without vascular risk factors. The 
effects of treatment were greater in subjects with vascular 
risk factors, Modiﬁ  ed Hachinski Ischemic Score (MHIS) > 0, 
(ADAS-Cog, PDS, MMSE, and GDS mean change from 
baseline scores). The treatment difference at 26 weeks for 
MHIS > 0 patients receiving rivastigmine 6–12 mg/day ver-
sus placebo was 6.15 points on the ADAS-Cog. While the 
mean 6–12 mg/day and placebo difference on ADAS-Cog 
was larger in patients with vascular risk factors compared 
with those without, this difference in effect size is attributed 
to the greater improvement from baseline in the MHIS > 0 
category 6–12 mg group. 
The clinical utility of the cognitive effects is supported 
by the beneﬁ  ts seen in the ADL. Whereas a signiﬁ  cant im-
provement was seen in AD patients with or without vascular 
risk factors, the treatment differences were greater for the 
group with vascular risk factors. These effects were also 
reinforced by the GDS and MMSE scores observed in these 
patients. The CIBIC-Plus results show greater beneﬁ  ts in the 
MHIS > 0 category for 6–12 mg/day and 1–4mg/day. In 
addition, no statistically signiﬁ  cant difference was observed 
in the MHIS > 0 group, 6–12 mg/day, compared with the 
placebo group MHIS > 0 (Figures 5, 6, 7, 8).
Rivastigmine for subcortical 
vascular dementia
Moretti and colleagues (2004) have recently described the 
different studies on rivastigmine in the treatment of vascular 
dementia (VaD). Given the range of clinical syndromes in VaD, 
all open-label clinical trials have been conducted on patients with 
subcortical VaD (Roman et al 2000). This form of VaD is char-
acterized by executive dysfunctions (Roman and Royall 1999), 
abnormal gait, urinary urgency, and incontinence, resulting from 
the interruption of prefrontal-subcortical circuits due to lacunar 
stroke and white-matter lesions (Roman et al 2004).Clinical Interventions in Aging 2007:2(1) 27
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Rivastigmine was used in small open-label studies 
of patients with subcortical VaD followed for 12 months 
(Moretti et al 2001) and 22 months (Moretti et al 2002); 
rivastigmine proved useful in stabilizing cognitive function 
and ADL, with an improvement in cognitive function, 
planning, and behavior, and in reducing caregiver stress. 
Moretti and colleagues (2002) concluded that long-term 
rivastigmine treatment in patients with subcortical VaD is 
safe and effective. The improvements were in the domains 
that characterize subcortical VaD. The effects of rivastigmine 
have yet to be validated in large-scale, Phase III, randomized 
double-blind placebo-controlled clinical trials.
As regards the use of rivastigmine in patients with AD 
and CVD, Kumar and colleagues (2000) compared outcomes 
in AD patients with and without risk factors; cognitive 
effects were seen in both groups but the patients with AD 
and vascular risk factors experienced greater beneﬁ  ts. These 
conclusions were conﬁ  rmed by Erkinjuntti and colleagues 
(2002) in a 104-week open-label study. Compared with 
nonhypertensive AD patients, signiﬁ  cant differences were 
seen on the PDS in the hypertensive group. Erkinjuntti 
and colleagues (2003) analyzed 725 AD patients treated 
with rivastigmine according to the presence of arterial 
hypertension at baseline. Rivastigmine 6–12 mg/day 
improves PDS outcomes more than placebo in hypertensive 
subjects (p = 0.031) and nonhypertensive subjects (p = 0.035). 
All patients receiving rivastigmine 6–12 mg/day had higher 
CIBIC-plus scores compared with the placebo group. The 
beneﬁ  ts on disease progression experienced by the patients 
with AD and hypertension could be due to the effects of the 
drug on cerebrovascular factors or to a greater cholinergic 
deﬁ  cit of patients with AD and hypertension.
Neuroprotection
Acetylcholinesterase inhibitors (AChEls) are the mainstay 
of pharmacological treatment of AD. Andin’s study (2005) 
provides the ﬁ  rst evidence that the glutamatergic system is 
modulated following AChE inhibition by rivastigmine; a 
ﬁ  nding which is likely to be of importance for the clinical 
effects. An in situ hybridization technique (using digoxigenin-
labeled cRNA probes) was used to elucidate changes in 
mRNA expression of the neuronal glutamate transporter, rat 
Figure 5 ADAS-cog mean change from baseline scores at week 26. 
Note:  MHIS = 0; 
 MHIS = 1
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excitatory amino carrier 1 (rEAAC1), after treatment with the 
AChEl rivastigmine. Compared with saline-treated rats, the 
rats subchronically (3 days) and chronically (21 days), but 
not acutely, treated with rivastigmine showed a signiﬁ  cant 
increase in rEAAC1 mRNA expression in the hippocampal 
areas cornu anterior 1 (CA1), CA2, CA3 and dentate gyrus 
(p<0.01), but not in cortical areas. 
Numerous studies have investigated the neurotoxic effects 
of the abnormal production of ß-amyloid. Mesulam and Geula 
(1994) hypothesized a two-stage evolution of ß-amyloid 
plaques with a secondary development of local neurotoxicity 
due to the increase of butyrylcholinesterase at the plaque 
level. A study conducted by Venneri and colleagues (2005) 
to monitor white matter density in a group of 26 patients 
treated with the three inhibitors showed less worsening of 
parietotemporal atrophy in subjects taking rivastigmine. This 
ﬁ  nding provided empirical evidence that dual inhibition may 
have potential neuroprotective effects.
Rivastigmine, with its dual action on AChE and BuChE 
especially in the hippocampus and neurocortex, may lead to 
Figure 6 PDS mean change from baseline score at week 26. 
Notes:  MHIS = 0; 
 MHIS>0. 





Placebo −  5.6 ± 1.01 − 6.3 ± 1.18
Rivastigmine 1– 4mg/day −  6.6 ± 1.044 −3.8 ± 0.88
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Placebo 4.54 ± 0.093  4.4 ± 0.13
4.17 ± 0.12  4.23 ± 0.10
4.21 ± 0.14  4.12 ± 0.14
Rivastigmine 1– 4mg/day
Rivastigmine 6–12mg/day
Figure 7 CIBIC-plus mean score for population. 
Notes:  MHIS = 0; 
 MHIS > 0.
Abbreviations: CIBIC-plus, Clinician Interview-Based Impression of Change-plus; MHIS, Modiﬁ  ed Hachinski Ischemic Score; SD, standard deviation. 
an increase in acetylcholine concentration and a reduction 
in noradrenaline and tau in the rat hippocampus. Trabace 
and colleagues (2000) found that rivastigmine also 
affects the glutaminergic system leading to increased 
glutamate concentration in the rat hippocampus, although 
the mechanisms are not completely clear. A study by 
Andin and colleagues (2005) has shown that rivastigmine 
modulates glutaminergic activity by interfering with the 
regulation of activity of some genes. This finding could 
have implications for the efficacy of rivastigmine in the 
treatment of AD.
Conclusion
The regional brain atropy which accompanies the cognitive 
and functional decline in AD has, in principle, been related to 
progressive neuropathological changes in that disorder. Stud-
ies investigating the possible neurotoxic processes related to 
the distinctive neuropathology of AD have emphasized the Clinical Interventions in Aging 2007:2(1) 30
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possible role of abnormal β-amyloid production. They have 
argued for a two-stage evolution of senile amyloid plaques 
with a secondary development of local neurotoxicity, for 
which increased levels of BChE in the plaque structure 
may be a marker and putative toxic agent (Mesulam 
and Geula 1994). As a test of concept, this proposed 
neurodegenerative process might be investigated clini-
cally by taking advantage of the differing actions of the 
cholinesterase inhibitors that are widely used in the hope 
of achieving symptomatic benefits for AD patients. Done-
pezil and galantamine are selective for AChE inhibition, 
whereas rivastigmine provides an additional inhibitory 
action on BChE and might have an effect on local plaque 
toxicity.
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